The object of insurance is the Insured's property interests related to the emergence of its liability for compensation for harm caused to the life or health of the Patient as a result of conducting clinical studies of a pharmacological or medicinal product on the Patient during the validity period of the Insurance Contract.

Risks

 Arising of the liability of policyholder for compensation for harm caused to the life or health of the patient as a result of clinical studies of a pharmacological or medicinal product on the patient during the validity of this Agreement. The insurance cover age also applies to cases of harm to the life and health of the patient that occurred within one year after the end of clinical trials conducted during the validity period of this treaty, provided that there is evidence of a causal relationship between ongoing clinical studies and the fact of causing harm to the patient.

The insurance amount (liability)

By the agreement of parties

Insurance tariff

From 1% up to 3% of the insured amount depending on the degree of risk

Terms of Payment of Insurance premiums:

  • Lump-sum
  • Quarterly

The current proposal is considered as preliminary and the conditions set forth in it are subject to change.